Charlie Gourley graduated with Genetics and Medicine degrees from Glasgow University, UK, in 1991 and 1994, respectively. From 1998 to 2005, he trained in medical oncology at the Edinburgh Cancer Centre, UK, during which he was awarded a Ph.D. in ovarian cancer genetics from the University of Edinburgh and an NHS Education for Scotland Clinician Scientist Award. He was appointed as Senior Lecturer in Medical Oncology at the University of Edinburgh in 2005, Reader in Medical Oncology in 2011, and Professor of Medical Oncology (Personal Chair) in 2012. He received a Scottish Senior Clinical Fellowship Award in 2010. He became Director of the Nicola Murray Centre for Ovarian Cancer Research in 2016, Clinical Director of the Cancer Research UK (CRUK) Edinburgh Centre in 2019, and Clinical Director of the Cancer Research UK Scotland Centre in 2022. He is a member of the CRUK Clinical Research Committee and the German Cancer Aid Scientific Review Committee. His clinical research focus is ovarian cancer clinical trials. His translational research focuses on the genomic characterisation of ovarian cancer in order to facilitate the discovery of biomarkers of ovarian cancer drug sensitivity and resistance.
Charlie Gourley graduated with Genetics and Medicine degrees from Glasgow University, UK, in 1991 and 1994, respectively. From 1998 to 2005, he trained in medical oncology at the Edinburgh Cancer Centre, UK, during which he was awarded a Ph.D. in ovarian cancer genetics from the University of Edinburgh and an NHS Education for Scotland Clinician Scientist Award. He was appointed as Senior Lecturer in Medical Oncology at the University of Edinburgh in 2005, Reader in Medical Oncology in 2011, and Professor of Medical Oncology (Personal Chair) in 2012. He received a Scottish Senior Clinical Fellowship Award in 2010. He became Director of the Nicola Murray Centre for Ovarian Cancer Research in 2016, Clinical Director of the Cancer Research UK (CRUK) Edinburgh Centre in 2019, and Clinical Director of the Cancer Research UK Scotland Centre in 2022. He is a member of the CRUK Clinical Research Committee and the German Cancer Aid Scientific Review Committee. His clinical research focus is ovarian cancer clinical trials. His translational research focuses on the genomic characterisation of ovarian cancer in order to facilitate the discovery of biomarkers of ovarian cancer drug sensitivity and resistance.